Company intelligence
NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research
20,000+ Monoclonal/Recombinant Abs | Trusted by Global Life Science Leaders for Monospecificity & Reproducibility
About NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research
Unreliable antibodies are one of the most expensive problems in life science research. NeoBiotechnologies was founded to solve it. We are an original manufacturer of 20,000+ validated monospecific monoclonal antibodies for cancer research, diagnostics, neuroscience, immunology, and signal transduction. Founded by Dr. Atul K. Tandon, the pioneer behind NeoMarkers (now part of Thermo Fisher Scientific), every antibody in our catalog is developed, validated, and quality-controlled entirely in-house across Western blot, IHC, immunofluorescence, and flow cytometry, with select antibodies screened against HuProt™ human proteome microarrays for confirmed monospecificity. We supply leading life science companies through OEM and private label partnerships, and serve researchers and pathologists worldwide. Orders ship in 1–2 business days, backed by a performance guarantee. Science deserves antibodies that work, every time.
Verified activity
Signals from NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research
4 published signals
Partnerships
NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research announced a strategic agreement with Styx Biotechnologies and ZoeNCure Therapeutics to advance their next-generation ADC pipeline into first-in-human clinical development.
Reported by NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research
Partnerships
NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research announced an official distribution partnership with Amsbio to bring its validated monoclonal antibody range to North America researchers.
Reported by NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research
Research & Knowledge
NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research demonstrated detection of GABBR2 using the GABBR2/7859 Mouse Monoclonal Antibody in Western blot analysis.
Reported by NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research
Research & Knowledge
NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research put together a quick breakdown of what's happening, the science behind Ewing sarcoma, and how it's diagnosed.
Reported by NeoBiotechnologies | Recombinant Monoclonal Antibodies for Cancer Research